MetaCap

Rafael (RFL) vs Tonix Pharmaceuticals (TNXP)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Rafael (RFL) has outperformed Tonix Pharmaceuticals (TNXP) over the past year, losing 25.8% versus a loss of 85.2%. Over five years, RFL leads with a -84.2% price change compared with -100.0% for TNXP. Rafael is the larger company by market cap ($48.0 million vs $46.2 million), about 1.0 times the size, while Tonix Pharmaceuticals is growing revenue faster (+29.8% vs -4.7%).

Tonix Pharmaceuticals converts more of its revenue into profit, with a net margin of -946.2% versus -3390.7%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

RFL-25.83%TNXP-85.22%
+219%+60%-100%
Nov 21, 20251 yearNov 20, 2026
RFL-84.64%TNXP-100.00%
+12%-47%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

RFL versus TNXP key metrics
MetricRFLTNXP
Share price$0.9197$2.38
Market cap$47.99M$46.25M
1-day change+2.19%-6.67%
YTD return-22.06%-84.76%
1-year return-25.83%-85.22%
5-year return-84.19%-100.00%
EPS (TTM)$-0.58$-12.39
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$874.00K$13.11M
Revenue growth (YoY)-4.69%+29.85%
Net income (latest FY)$-29.64M$-124.02M
Gross margin—49.34%
Operating margin-3822.54%-959.05%
Net margin-3390.73%-946.22%
52-week high$3.96$20.56
52-week low$0.781$2.30
Distance from 52-week high-76.78%-88.42%
Analyst consensus—strong_buy
Avg. price target upside—+1769.75%
Average volume140.84K838.83K
Shares outstanding51.39M19.43M
Employees21142
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • RFL has outperformed TNXP by 59.4 percentage points over the past year.
  • Tonix Pharmaceuticals is more profitable, keeping -946.2 cents of every revenue dollar as net income versus -3390.7 cents for Rafael.
  • Tonix Pharmaceuticals grew revenue faster in its latest fiscal year (+29.85% vs -4.69%).

About Rafael

RFL stock →

Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel.

Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees

About Tonix Pharmaceuticals

TNXP stock →

Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia.

Health Care · Biotechnology: Pharmaceutical Preparations · 142 employees

RFL vs TNXP FAQ

Which is bigger, Rafael or Tonix Pharmaceuticals?

Rafael (RFL) is larger, with a market capitalization of $47.99M compared with $46.25M for Tonix Pharmaceuticals (TNXP).

Which stock has performed better over the past year, RFL or TNXP?

RFL returned -25.83% over the past 12 months, compared with -85.22% for TNXP (price return, excluding dividends). Past performance does not predict future results.

Are Rafael and Tonix Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons